NEW YORK, May 31, 2012 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC announces that a class action suit was filed in the United States District Court for the District Court of the Virgin Islands on behalf of purchasers of the common stock of Tibet Pharmaceuticals, Inc. ("Tibet Pharmaceuticals" or the "Company") (OTC Markets: TBET -News), who purchased shares after December 28, 2010 (the "Class Period").
The Complaint asserts violations of the federal securities laws against Tibet Pharmaceuticals, its officers and directors, and underwriters for issuing inaccurate statements of material fact about the Company's true financial and business condition, which ultimately caused the Tibet Pharmaceutical's stock to be halted by the NASDAQ and delisted. The Complaint alleges defendants misrepresented and failed to disclose material internal control deficiencies, which rendered the Company's registration statement and prospectus to be materially false and misleading.
No Class has yet been certified in the above action. If you wish to review a copy of the Complaint, to discuss this action, or have any questions, please contact either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. July 25, 2012 is the deadline for investors to seek a lead plaintiff appointment.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Eitan Kimelman, 212-697-6484 firstname.lastname@example.org SOURCE Bronstein, Gewirtz & Grossman, LLC
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV